-- Scott Roberts
TUESDAY, Oct. 1 (HealthDay News) -- Brintellix (vortioxetine)
has been approved by the U.S. Food and Drug Administration to treat
adults with major depressive disorder, often referred to as
The disorder may have symptoms including lack of interest in
usual activities, weight or appetite changes, sleep problems,
feelings of guilt or worthlessness, lack of concentration and
thoughts of suicide.
In seven clinical studies, Brintellix proved effective in
treating depression and in preventing future episodes, the FDA said
in a news release. The most common side effects observed included
nausea, constipation and vomiting.
Brintellix has a boxed label warning that antidepressants can
raise the risk of suicidal thoughts among some users, especially
among children, adolescents and adults aged 18 to 24. Doctors
should carefully monitor users of Brintellix and similar drugs,
especially during initial treatment, the FDA advised.
Brintellix is marketed by Takeda Pharmaceuticals and Lunbeck,
both based in Deerfield, Ill.
The U.S. National Institute of Mental Health has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.